Understanding Dimethyl Fumarate’s Impact on Radiologically Isolated Syndrome

RIS was first defined by Darin Okuda, MD, as showing T2-hyperintense, ovoid, homogenous, well-defined lesions on MRI that fulfilled at least 3 of 4 Barkhof criteria. More than a decade later, in 2022, he and his colleagues unveiled findings from the ARISE study (NCT02739542), the first trial to identify a disease-modifying effect in RIS through treatment. The drug used in the study was dimethyl fumarate (Tecfidera; Biogen), a nuclear factor 2 activator that received FDA-approval for relapsing MS in 2013.

The full dataset of ARISE was recently published in Annals of Neurology, with findings that showed a significant 82% reduction in risk of clinical demyelinating event over a 96-week treatment period. Okuda, director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center, sat down to describe the design of the study and the significance of these data.

(https://www.neurologylive.com/view/un...)

More Content:
-Darin Okuda, MD (https://www.neurologylive.com/authors...)
-Full Data Set of ARISE (https://www.neurologylive.com/view/ar...)